Dr. Fakeeh Hospital Q1 2026 Net Profit Falls 46.8%
Dr. Soliman Abdul Kader Fakeeh Hospital (4017) announced Q1 2026 interim results with net profit declining 46.8% YoY to SAR 38.41 million, affected by Ramadan and Eid Al Fitr seasonality and ramp-up costs at its Madinah hospital. Revenue increased 3.3% to SAR 724.15 million, driven by higher patient volumes and surgical procedures.
Key Numbers
Dr. Soliman Abdul Kader Fakeeh Hospital Co. (4017) reported its interim financial results for the three months ended March 31, 2026. Net profit fell 46.8% year-on-year to SAR 38.41 million, while revenue grew 3.3% to SAR 724.15 million.
Key Financial Results
| Metric | Q1 2026 | Q1 2025 | Change |
|---|---|---|---|
| Revenue | SAR 724.15M | SAR 701.02M | +3.3% |
| Net Profit | SAR 38.41M | SAR 72.24M | -46.8% |
| EPS | SAR 0.17 | SAR 0.31 | -45.2% |
Highlights from the Announcement
- Revenue: Grew 3.3% YoY, driven by a 1% increase in outpatients, 11% increase in inpatients, and 17% rise in surgical procedures. New business revenue from DSFH Riyadh and DSFH Madinah expansions surged 78%.
- Net Profit: Declined primarily due to prolonged Ramadan and Eid Al Fitr seasonality, which reduced effective operating days and spread fixed costs over a smaller revenue base. Ramp-up costs at DSFH Madinah, including front-loaded staffing and depreciation, also weighed on profitability.
- Quarter-on-Quarter: Revenue fell 9.4% and net profit dropped 40.2% compared to Q4 2025.
- Shareholders' Equity: Increased 1.25% YoY to SAR 3.21 billion.
- Auditor's Opinion: Unmodified conclusion with no additional comments.
Future Guidance
No explicit guidance was provided in the announcement.
Impact on the Stock
The earnings miss is likely to pressure the stock in the near term, given the sharp profit decline and ongoing cost headwinds. However, strong revenue growth and expansion in Riyadh and Madinah may support long-term investor confidence.
What This Means for Investors
Dr. Fakeeh Hospital faces seasonal and expansion-related cost pressures, but operational fundamentals (patient growth, surgical volumes) remain solid. Investors should monitor the ramp-up of new hospitals and their path to profitability in coming quarters.
Frequently Asked Questions
Found this useful? Share it